Relationship to the Confidentiality Agreement. This Agreement supersedes the Confidentiality Agreement, provided that all “Confidential Information” disclosed or received by the Parties thereunder shall be deemed “Confidential Information” hereunder and shall be subject to the terms and conditions of this Agreement.
Relationship to the Confidentiality Agreement. This Agreement supersedes that certain “Mutual Confidential Non-Disclosure Agreement” between the parties dated June 22, 2012; provided that all “Confidential Information” (as defined in that agreement) that was disclosed or received by the parties thereunder will also be deemed to be “Confidential Information” for purposes of this Agreement and will be subject to the terms and conditions of this Agreement.
Relationship to the Confidentiality Agreement. All “Confidential Information” disclosed or received by or on behalf of a Party under that certain Confidential Disclosure Agreement between Amgen and Xxxxxxx Xxxxxxx Xxxxxxxx & Xxxxx, dated October 17, 2011, shall be deemed “Confidential Information” hereunder and shall be subject to the terms and conditions of this Agreement.
Relationship to the Confidentiality Agreement. This Agreement supersedes the Confidentiality Agreement; provided, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement. [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
Relationship to the Confidentiality Agreement. This Agreement supersedes that certain Confidential Disclosure Agreement between the Parties dated March 9, 2017, as amended by Amendment Number 1 to Confidential Disclosure Agreement Number [***] dated March 14, 2017; provided, however, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement.
Relationship to the Confidentiality Agreement. This Agreement supersedes that certain Confidential Disclosure Agreement between AMGEN and RBNC [***]; provided, however, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed either “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement or treated as “Confidential Information” under either the Exclusive License Agreement for GCase or the Research Collaboration and License Agreement and subject to the terms and conditions of such agreement, as applicable in light of the subject matter of such disclosure; provided that if such information relates to both this Agreement and such other agreements, or does not relate specifically to any such agreement, then such information will be deemed “Confidential Information” hereunder and subject to the terms and conditions of this Agreement.
Relationship to the Confidentiality Agreement. This Agreement supersedes that certain “Mutual Confidentiality Agreement” between the Parties dated July 8, 2009 (the “Confidentiality Agreement”); provided that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement.
Relationship to the Confidentiality Agreement. This Agreement is in addition to certain “Confidentiality Agreements” between the Parties dated the 1st of January, 2014, and the 4th of January, 2017, and (a) all “Confidential Information” as defined therein that is disclosed or received by the Parties prior to the Effective Date shall continue to be subject to the terms and conditions of the Confidentiality Agreement and (b) all Confidential Information disclosed or received by the Parties following the Effective Date shall be subject to the terms and conditions of this Agreement. For the avoidance of doubt, all other confidentiality agreements concluded between Cellscript and Company prior to the Effective Date of this Agreement shall be superseded by this Agreement.
Relationship to the Confidentiality Agreement. This Agreement supersedes that certain “Mutual Confidentiality Agreement” between the Parties dated May 21, 2012; provided that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Relationship to the Confidentiality Agreement. All “Confidential Information” disclosed or received by or on behalf of a Party under that certain Confidential Disclosure Agreement between Amgen and Xxxxxxx Xxxxxxx Xxxxxxxx & Xxxxx, dated October 17, 2011, shall be deemed “Confidential Information” hereunder and shall be subject to the terms and conditions of this Agreement. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
